Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune factor VIII inhibitors.

R K Pruthi1, W L Nichols

  • 1Department of Internal Medicine and Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. pruthi.rajiv@mayo.edu

Current Opinion in Hematology
|September 1, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coagulation abnormalities and haemostatic surgical outcomes in 142 patients with Noonan syndrome.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Optimal utilization of thrombophilia testing.

International journal of laboratory hematology·2017
Same author

A single-centre study of haemostatic outcomes of joint replacement in von Willebrand disease and control patients and an analysis of the literature.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Four-factor prothrombin complex concentrates for warfarin reversal: do real-world outcomes differ from controlled clinical trials?

Transfusion·2016
Same author

Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.

European journal of internal medicine·2016
Same author

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Spontaneous inhibitors to factor VIII (FVIII) cause severe bleeding. Diagnosis is complex, but porcine FVIII and recombinant activated factor VII offer therapeutic options, with ongoing research into engineered FVIII and immunosuppression.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Acquired inhibitors to factor VIII (FVIII) are rare but cause life-threatening hemorrhage.
  • Diagnosis often involves complex assays to detect and quantify inhibitor antibodies.
  • Current treatments include bypassing agents and consideration of porcine FVIII due to low cross-reactivity.

Purpose of the Study:

  • To review the diagnostic challenges and therapeutic advancements for acquired FVIII inhibitors.
  • To discuss emerging treatment strategies, including recombinant activated factor VII and genetically engineered FVIII.
  • To highlight the need for further research in immunosuppressive therapy.

Main Methods:

  • Literature review of diagnostic techniques for FVIII inhibitors.

Related Experiment Videos

  • Analysis of therapeutic options for acquired hemophilia A.
  • Discussion of immunomodulatory approaches and epitope mapping.

    • Main Results:

    • Low cross-reactivity of inhibitors to porcine FVIII supports its therapeutic utility.
    • Recombinant activated factor VII provides an alternative to prothrombin complex concentrates.
    • Engineered FVIII molecules aid in defining immunodominant epitopes.

    Conclusions:

    • Effective management of FVIII inhibitors requires accurate diagnosis and tailored therapy.
    • Novel therapeutic agents and strategies are expanding treatment possibilities.
    • Further research is crucial to optimize immunosuppression and advance patient care.